Biomarkers of Parkinson's disease: Current status and future perspectives

Drug Discovery Today

Volumn 18, Issue 3-4, 2013, Pages 155-162

  Wang, Jian ^a   Hoekstra, Jake G ^b   Zuo, Chuantao ^a   Cook, Travis J ^c   Zhang, Jing ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BIOCHEMICAL MARKER; BIOLOGICAL MARKER; DJ 1 PROTEIN; DOPAMINE TRANSPORTER; TAU PROTEIN; VESICULAR MONOAMINE TRANSPORTER 2;

CEREBROSPINAL FLUID; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE COURSE; GENE EXPRESSION PROFILING; HUMAN; METABOLOMICS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BIOLOGICAL MARKERS; HUMANS; NEUROIMAGING; PARKINSON DISEASE;

EID: 84873094123     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.09.001     Document Type: Review

References (87)

1. H. Braak Staging of brain pathology related to sporadic Parkinson's disease Neurobiol. Aging 24 2003 197 211
2. J. Meara Accuracy of diagnosis in patients with presumed Parkinson's disease Age Ageing 28 1999 99 102
3. 18F]dopa PET J. Neurol. Neurosurg. Psychiatry 64 1998 314 319
4. J.M. Fearnley, and A.J. Lees Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 1991 2283 2301
5. 18F] dopa PET findings in early Parkinson's disease J. Neurol. Neurosurg. Psychiatry 59 1995 597 600
6. D.J. Brooks The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET Brain 113 1990 1539 1552
7. F.J. Vingerhoets Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann. Neurol. 41 1997 58 64
8. M.J. Ribeiro Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease Arch. Neurol. 59 2002 580 586
9. D.J. Brooks, and N. Pavese Imaging biomarkers in Parkinson's disease Prog. Neurobiol. 95 2011 614 628
10. 123I]-FP-CIT study group Mov. Disord. 15 2000 503 510
11. V.L. Marshall Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging Nucl. Med. Commun. 27 2006 933 937
12. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages J. Neurol. 254 2007 185 190
13. S. Fahn Levodopa and the progression of Parkinson's disease N. Engl. J. Med. 351 2004 2498 2508
14. N.I. Bohnen Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease J. Cereb. Blood Flow Metab. 26 2006 1198 1212
15. C.S. Lee In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease Ann. Neurol. 47 2000 493 503
16. N. Okamura In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133 J. Nucl. Med. 51 2010 223 228
17. N. Pavese Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease? Exp. Neurol. 233 2011 118 120
18. 123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis Arch. Neurol. 61 2004 1224 1229
19. G. Masilamoni (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism Exp. Neurol. 226 2010 265 273
20. J.O. Rinne PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease Mov. Disord. 8 1993 134 138
21. 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients J. Neural. Transm. 112 2005 677 692
22. A. Antonini Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease Brain 120 1997 2187 2195
23. D. Eidelberg The metabolic topography of parkinsonism J. Cereb. Blood Flow Metab. 14 1994 783 801
24. C.C. Tang Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis Lancet Neurol. 9 2010 149 158
25. C.C. Tang Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease J. Neurosci. 30 2010 1049 1056
26. Y. Ma Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility J. Cereb. Blood Flow Metab. 27 2007 597 605
27. K. Asanuma Network modulation in the treatment of Parkinson's disease Brain 129 2006 2667 2678
28. A. Feigin Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 104 2007 19559 19564
29. R. Hilker Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways Neurology 65 2005 1716 1722
30. W.R. Martin Midbrain iron content in early Parkinson disease: a potential biomarker of disease status Neurology 70 2008 1411 1417
31. C. Scherfler Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease Brain 129 2006 538 542
32. D.E. Vaillancourt High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease Neurology 72 2009 1378 1384
33. L.L. Chan Case control study of diffusion tensor imaging in Parkinson's disease J. Neurol. Neurosurg. Psychiatry 78 2007 1383 1386
34. M.H. Polymeropoulos Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
35. T.B. Ahn alpha-Synuclein gene duplication is present in sporadic Parkinson disease Neurology 70 2008 43 49
36. T. Tokuda Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease Biochem. Biophys. Res. Commun. 349 2006 162 166
37. B. Mollenhauer Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Exp. Neurol. 213 2008 315 325
38. Z. Hong DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease Brain 133 2010 713 726
39. B. Mollenhauer α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Lancet Neurol. 10 2011 230 240
40. T. Tokuda Detection of elevated levels of {alpha}-synuclein oligomers in CSF from patients with Parkinson disease Neurology 75 2010 1766 1770
41. O.M. El-Agnaf Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease FASEB J. 20 2006 419 425
42. Y. Wang Phosphorylated α-synuclein in Parkinson's disease Sci. Transl. Med. 4 2012 121ra120
43. M. Waragai Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease Biochem. Biophys. Res. Commun. 345 2006 967 972
44. M. Waragai Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease Neurosci. Lett. 425 2007 18 22
45. M. Shi Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease Neurosci. Lett. 480 2010 78 82
46. N. Pankratz Genomewide association study for susceptibility genes contributing to familial Parkinson disease Hum. Genet. 124 2009 593 605
47. W. Satake Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease Nat. Genet. 41 2009 1303 1307
48. T.J. Montine CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment Mov. Disord. 25 2010 2682 2685
49. M. Shi Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression Ann. Neurol. 69 2011 570 580
50. G. Alves CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study J. Neurol. Neurosurg. Psychiatry 81 2010 1080 1086
51. M. Buongiorno Amyloid-β and τ-biomarkers in Parkinson's disease-dementia J. Neurol. Sci. 310 2011 25 30
52. M. Bogdanov Metabolomic profiling to develop blood biomarkers for Parkinson's disease Brain 131 2008 389 396
53. W. Maetzler Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases Mov. Disord. 26 2011 176 181
54. K.K. Johansen Metabolomic profiling in LRRK2-related Parkinson's disease PLoS One 4 2009 E7551
55. A. Ascherio Urate as a predictor of the rate of clinical decline in Parkinson disease Arch. Neurol. 66 2009 1460 1468
56. C.C. Sun Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients Chin. Med. J. (Engl.) 125 2012 583 587
57. S.S. Ahmed Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection J. Biomed. Sci. 16 2009 63
58. C.R. Scherzer Molecular markers of early Parkinson's disease based on gene expression in blood Proc. Natl. Acad. Sci. U.S.A. 104 2007 955 960
59. M.I. Shadrina Expression analysis of suppression of tumorigenicity 13 gene in patients with Parkinson's disease Neurosci. Lett. 473 2010 257 259
60. E.V. Filatova Expression of GSK3B gene in peripheral blood in patient with Parkinson's disease Mol. Biol. 45 2011 459 463
61. E. Grünblatt Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease J. Neural. Transm. 117 2010 1387 1393
62. L. Molochnikov A molecular signature in blood identifies early Parkinson's disease Mol. Neurodegener. 7 2012 26
63. F. Abdi Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders J. Alzheimers Dis. 9 2006 293 348
64. J. Zhang CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases Am. J. Clin. Pathol. 129 2008 526 529
65. A. Sinha Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach Clin. Chim. Acta 400 2009 14 20
66. E.S. Wang Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease Acta Neurol. Scand. 122 2010 350 359
67. D. Berg Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings J. Neurol. 248 2001 684 689
68. A. Gaenslen The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study Lancet Neurol. 7 2008 417 424
69. A. Iranzo Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected] Lancet Neurol. 9 2010 1070 1077
70. D. Berg Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons Arch. Neurol. 68 2011 932 937
71. D. Berg Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease Mov. Disord. 20 2005 383 385
72. D.G. Healy Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study Lancet Neurol. 7 2008 583 590
73. J.R. Adams PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation Brain 128 2005 2777 2785
74. R. Nandhagopal Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study Neurology 71 2008 1790 1795
75. S. Kono Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism Mov. Disord. 25 2010 1823 1829
76. R.L. Doty Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease J. Neurol. Neurosurg. Psychiatry 55 1992 138 142
77. R.L. Doty Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease Neurology 43 1993 962 965
78. C.H. Schenck Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder Neurology 46 1996 388 393
79. M.L. Fantini Olfactory deficit in idiopathic rapid eye movements sleep behavior disorder Brain Res. Bull. 70 2006 386 390
80. M.M. Ponsen Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease J. Neurol. Neurosurg. Psychiatry 81 2010 396 399
81. I. Eisensehr Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls Brain 123 2000 1155 1160
82. K. Stiasny-Kolster Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT Brain 128 2005 126 137
83. J.O. Aasly Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers Neurology 78 2012 55 61
84. M. Shi DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function Neurobiol. Aging 33 2012 836.E835-836.E837
85. I. Devic Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease Brain 134 2011 E178
86. B.K. Madras Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain Synapse 29 1998 116 127
87. T. Eckert FDG PET in the differential diagnosis of parkinsonian disorders Neuroimage 26 2005 912 921